Skip to content

treatment of bell's palsy with intratympanic corticosteroid

intratympanic dexamethazone+ perdnislone +acycclovir versus prednislone + acyclovir in treatment of bell's palsy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200314046769N1
Enrollment
150
Registered
2020-06-16
Start date
2016-12-21
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bell's palsy. Bell's palsy

Interventions

Intervention 1: Intervention group: Treatment includes oral acyclovir and oral prednisolone at the same dose as the control and injection group dexamethasone between 2 and 3 mg intraperitoneally on t

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: The patient is available for six months from the start of treatment Complete unilateral Bell's palsy if they visit the center between one day and fourteen days after the onset of the disease and do not receive any other treatment. Age over 18 years

Exclusion criteria

Exclusion criteria: Acute or chronic otitis media Decreased new hearing at the same time as facial paralysis Fractures in the temporal bone on the same side or a history of acute trauma in the same direction as the paralysis. History of facial paralysis on the same side History of ear surgery on the same side Having Ramsey Hunt syndrome or skin lesions at the same time as facial paralysis Pregnancy mental illnesses A history of concomitant head and neck cancers High-dose corticosteroid contraindications such as a history of tuberculosis or active tuberculosis or active hepatitis B. unComplete Bell's palsy Failure to receive complete information on patient follow-up within six months of starting treatment

Design outcomes

Primary

MeasureTime frame
The rate of bell's palsy after treatment is based on the House-Berkman scale. Timepoint: The first day of study, three weeks after the start of treatment, six months after the start of treatment. Method of measurement: Facial paralysis is measured using the House-Berkman scale in clinic.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Ansari

Tehran University of Medical Sciences

ansari11192@yahoo.com+98 916 985 1160

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026